Quest Diagnostics (DGX) continues to maintain its market foothold through several notable initiatives. Continued revenue growth has managed to impress investors, as reaffirmed by the company’s Q1 2025 earnings call. However, despite achieving strong revenue growth, there has been a slight slump, with the share price undergoing minor adjustment. In its innovative strides, the company has debuted a testing methodology for the Oropouche virus, the first of its kind in the commercial market. It has also collaborated with MD Anderson Cancer Center to develop an MCaST blood test. Another instrumental development is the revolutionizing FDA-cleared blood test that detects early Alzheimer's disease with 97% accuracy. Among acquisitions, it sealed the deal with University Hospitals for the procurement of their Outreach Lab Services Business. On the downside, the stock has been experiencing some slide, raising questions about the market correcting itself. But, the stock seems undervalued, paving way for potential purchasing opportunities. Institutionally, Zacks and Barclays have retained favorable ratings and highlighted potential growth in future patient demand. As part of its aggressive growth strategy, the company will be delivering its strategic priorities at their 2025 Investor Day to drive sustainable growth and deliver long-term shareholder value.
Quest Diagnostics DGX News Analytics from Mon, 14 Oct 2024 07:00:00 GMT to Sat, 19 Jul 2025 10:42:43 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -3
